Bolt Biotherapeutics director granted 5,000 stock options
Bolt Biotherapeutics director Jakob Dupont received a stock option grant covering 5,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bolt Biotherapeutics director Jakob Dupont received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, with full vesting upon a change in control, assuming continuous service.
Insider Trade Summary
Grant/Award: 5,000 shares
Grant/Award
1 txn
Insider
Dupont Jakob
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Key Figures
Option grant size: 5,000 shares
Exercise price: $4.43 per share
Expiration date: June 9, 2036
+2 more
5 metrics
Option grant size
5,000 shares
Stock Option (Right to Buy) granted to director Jakob Dupont
Exercise price
$4.43 per share
Strike price of stock option grant
Expiration date
June 9, 2036
Option term end date for the grant
Shares underlying option
5,000 shares
Underlying common stock tied to the option
Vesting outside change in control
Earlier of June 9, 2027 or pre-annual meeting
Time-based vesting condition with continuous service
Key Terms
Stock Option (Right to Buy), exercise price, change in control, continuous service, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "4.4300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"the option will vest in full upon a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
continuous service financial
"subject to the Reporting Person's continuous service through such date"
annual meeting of stockholders financial
"the day immediately prior to the next annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bolt Biotherapeutics (BOLT) report for Jakob Dupont?
Bolt Biotherapeutics reported that director Jakob Dupont received a stock option grant for 5,000 shares. The option allows him to buy common stock at a fixed price, functioning as equity-based compensation rather than a market purchase or sale.
What are the key terms of Jakob Dupont’s Bolt Biotherapeutics stock option?
The stock option covers 5,000 shares of Bolt Biotherapeutics common stock at an exercise price of $4.43 per share. It expires on June 9, 2036, providing a long-dated incentive aligned with the company’s future performance and Dupont’s continued service.
How and when do Jakob Dupont’s Bolt Biotherapeutics options vest?
The options vest on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting. Vesting is conditioned on Jakob Dupont’s continuous service with Bolt Biotherapeutics through that date, aligning compensation with ongoing board participation.
What happens to Jakob Dupont’s Bolt Biotherapeutics options if there is a change in control?
If Bolt Biotherapeutics undergoes a change in control, Jakob Dupont’s stock option will vest in full. This means all 5,000 option shares become exercisable, accelerating vesting in connection with a significant corporate transaction affecting company ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
